Stay updated on Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    Added related topics: Lung cancer and MedlinePlus Genetics. Updated the page revision from v3.5.0 to v3.5.2.
    Difference
    0.2%
    Check dated 2026-04-17T14:13:13.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    Removed the Lung cancer topic and the MedlinePlus Genetics related topic from the study's topics section. This may reduce discoverability for NSCLC-related searches and related genetic resources.
    Difference
    0.1%
    Check dated 2026-04-10T09:00:25.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    Added related topics to the study page: Lung cancer and MedlinePlus Genetics.
    Difference
    0.1%
    Check dated 2026-04-03T05:39:05.000Z thumbnail image
  4. Check
    32 days ago
    Change Detected
    Summary
    The site was updated to Revision: v3.5.0, and Lung cancer, related topics (MedlinePlus Genetics), and Revision: v3.4.3 were removed.
    Difference
    0.2%
    Check dated 2026-03-19T23:42:15.000Z thumbnail image
  5. Check
    39 days ago
    Change Detected
    Summary
    Lung cancer is added as a related topic and a MedlinePlus Genetics link appears under related topics. The site revision is updated to v3.4.3, replacing v3.4.2.
    Difference
    0.2%
    Check dated 2026-03-12T20:41:38.000Z thumbnail image
  6. Check
    68 days ago
    Change Detected
    Summary
    - Minor metadata update: Revision: v3.4.2, and removal of a few related topics (Lung cancer; MedlinePlus Genetics; Revision: v3.4.1). Core study content, eligibility criteria, outcomes, and locations remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-02-11T23:59:35.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page.